Q4 2024 Theravance Biopharma Inc Earnings Call Transcript
Key Points
- Theravance Biopharma Inc (TBPH) reported a 10% increase in Upell net sales for the fourth quarter of 2024, reaching an all-time high of $66.7 million.
- The company achieved a $50 million milestone payment from Royalty Pharma based on 2024 trilogy net sales reported by GSK.
- Theravance Biopharma Inc (TBPH) is on track with the development timelines for amproloxetine, with solid enrollment in the Cyprus study and positive interactions with the FDA.
- The company has extended IP protection for Upell to 2039, providing long-term revenue potential.
- Theravance Biopharma Inc (TBPH) maintained strong expense management, delivering full-year results within guidance ranges and ending the year with $88 million in cash, excluding recent milestone receipts.
- Theravance Biopharma Inc (TBPH) anticipates typical seasonal dips in reported net sales as they transition from the fourth quarter to the first quarter of the following year.
- The company faces potential challenges in achieving the remaining $150 million of trilogy milestones, with recognition of other income only if cumulative milestones exceed $194 million.
- Operating expenses increased due to incremental commercial and medical affairs spend on amproloxetine pre-launch activities and increased R&D expenses.
- The company is waiting for regulatory decisions in China, which could impact the timing of potential sales milestones and royalties.
- Theravance Biopharma Inc (TBPH) has not yet increased the size of its commercial organization for amproloxetine, pending the results of the Cyprus study, which could delay market readiness.
Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma fourth quarter and full year 2024 conference call.(Operator Instructions) I will repeat these instructions after management completes their prepared remarks. Also, today's conference call is being recorded, and
Now I'd like to turn the call over to Rick Winningham, Chief Executive Officer; Please go ahead, sir.
Yeah, good afternoon and welcome to Theravans BioPharma's 4th quarter 2024 earnings results conference call. On slide 2, you'll find our forward-looking statements disclaimer, which covers certain risk factors, which could cause actual results to differ materially from any forward-looking statements we might make in today's call, and which are further described in our filings with the SEC.
Moving to slide 3, I'm joined today by Rhonda Farnum, Chief Business Officer, Anya Miller, head of development, and Aziz Swaft, Chief Financial Officer.
On
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
